Table 2 Effect and prognosis of colorectal cancer patients compared to BEV addition
Outcomes | Control | Number of study | Effect and 95%CI | I2 | P |
|---|---|---|---|---|---|
ORR | Placebo | 4 | 0.73(0.55,0.96) | 42.7% | 0.155 |
VAN | 1 | 1.26(0.71,2.24) | - | - | |
CED | 2 | 1.63(0.92,2.87) | 0% | 0.922 | |
PAN | 1 | 0.07(0.02,0.25) | - | - | |
DCR | Placebo | 4 | 1.13(0.77,1.66) | 0% | 0.941 |
CET | 2 | 1.71(0.97,3.00) | 0% | 0.320 | |
CED | 2 | 1.94(1.06,3.55) | 0% | 0.374 | |
PAN | 1 | 0.92(0.36,2.31) | - | - | |
OS | Placebo | 6 | 1.13(0.91,1.42) | 56.2% | 0.044 |
CET | 3 | 0.84(0.75,0.94) | 0% | 0.511 | |
PAN | 1 | 0.86(0.56,1.32) | - | - | |
PFS | Placebo | 5 | 1.20(1.06,1.37) | 0% | 0.690 |
CET | 3 | 0.93(0.83,1.04) | 0% | 0.752 | |
CED | 2 | 1.22(0.91,1.64) | 0% | 0.764 | |
PAN | 1 | 0.88(0.60,1.29) | - | - |